conference widget

If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing, according to GSK.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

The investigational once-daily oral analgesic, a potent inhibitor of a novel target for neuropathic pain, achieved meaningful pain reduction vs placebo.

Listen to our latest podcast episode with Heather Yun, MD, for details on emerging pathogens, the role of primary care clinicians in the effort to rein in antimicrobial resistance, and more.

Participants (aged 6 to 17 years) receiving neffy vs standard treatments had fewer skin, gastrointestinal, and respiratory symptoms at 15, 5, and 5 minutes, respectively.

AAAAI 2025: Dupilumab was associated with a 56.9% reduction in IgE levels at 12 months and of 73.5% at 24 months, according to results presented at AAAAI 2025.